Valneva SE
valneva.comWhat Do They Do?
Sells IXIARO, a Japanese encephalitis vaccine, to travelers and military customers, and develops, manufactures and sells other preventive vaccines for infectious diseases.
20-F for FY2025, filed Mar 17, 2026We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing…View ↗
We commercialize a portfolio of proprietary and differentiated traveler vaccines, which is composed of IXIARO (also marketed as JESPECT in…View ↗
We have established our own commercial operations in certain travel vaccine markets including the United States, Canada, the United…View ↗
Who Are Their Customers?
Private and government customers, including the U.S. military, buy through Valneva’s own sales operations in some markets; elsewhere, specialist partners distribute its vaccines. Most product sales go through distributors, while sales to retailers and the U.S. Department of Defense are direct.
20-F for FY2025, filed Mar 17, 2026We have established our own commercial operations in certain travel vaccine markets including the United States, Canada, the United…View ↗
We manage nearly all of our global product sales revenues through our own commercial operations. Local operations include expertise in…View ↗
The Group’s product sales contracts generally include one type of performance obligation. Revenue is recognized at the point in time when…View ↗
In most cases, Valneva sells its products through distributors. Valneva is acting as principal given that it controls such products before…View ↗
How Are They Changing?
Chikungunya vaccine commercialization
The older report described a chikungunya vaccine candidate in clinical development; the latest describes a marketed chikungunya vaccine alongside Valneva’s traveler vaccines.
20-F for FY2022, filed Mar 30, 2023 20-F for FY2025, filed Mar 17, 2026VLA1553 – a vaccine candidate against the chikungunya virus, or CHIKV, a mosquito-borne virus that has spread to more than 100 countries…View ↗
Who Do They Compete With?
Competes with Biken, Kaketsuken, Chengdu, Sanofi, Substipharm, Moderna, Ixodes, Takeda Pharmaceuticals, Tonix Pharmaceuticals, Inovio Pharmaceuticals, Tarsus, Euroimmun, GlaxoSmithKline, Baxter, Beijing Zhifei Lvzhu, Institut Pasteur, and GVGH
20-F for FY2025, filed Mar 17, 2026Given the large population in the Japanese encephalitis endemic region, consisting of over 3 billion people, and the inclusion of the…View ↗
Loading...
